3,149
Views
3
CrossRef citations to date
0
Altmetric
Oncology

Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States

, , , , , , , , , & show all
Pages 660-668 | Received 10 Feb 2022, Accepted 28 Feb 2022, Published online: 06 Jun 2022